Regeneron Pharmaceuticals
New York, NY

Dr. Israel Lowy is the vice president of Clinical Sciences and the head of Translational Science and of Oncology at Regeneron Pharmaceuticals, where he has focused on developing novel immunotherapies, antibody-drug conjugates, and treatments that target tumor blood vessels. Dr. Lowy is a member of CRI’s Cancer Immunotherapy Consortium (CIC) Steering Committee.

I believe this area is poised for a renaissance to identify new, precise antibody therapeutic candidates.
Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.